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Abstract 
Stroke is the second leading cause of death and a major cause of disability worldwide. Its 
indicence is increasing because the population ages. In addition, more young people are affected 
by stroke in low and middle income countries. Ischemic stroke is more frequent but hemorrhagic 
stroke is responsible for more deaths and disability adjusted life years lost. Incidence and 
mortality of stroke differ between countries, geographical regions and ethnic groups. In high 
income countries mainly, improvements in prevention, acute treatment and neurorehabilitation 
have lead to a substantial decrease in the burden of stroke over the past 30 years. This article 
reviews epidemiological and clinical data concerning stroke indicende and burden around the 
globe. 
Stroke burden, costs and disparities  
The latest estimate from the Global Burden of Disease, Injuries and Risk Factors Study (GBD 
2015) revealed a further shift from communicable diseases, maternal and nutritional causes 
towards non-communicable diseases like stroke. This effect of likely caused by increase and 
aging of the world’s population as well as by global decreased death rates in the last decades1.  
The most prominent causes of death are vascular in nature and stroke is currently still the second 
leading cause of death worldwide 2. Ischaemic heart disease and stroke together accounted for 
15·2 million deaths (15·0 million to 15·6 million) in 2015 2. 
 Currently, approximately 3-4% of total health care expenditures in Western countries are 
spent on stroke3. The mean lifetime cost of ischemic stroke per person, which includes inpatient 
care, rehabilitation, and follow-up care, is estimated at $140,048 in the US4.  
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The total annual direct costs were estimated at €26.6 billion in 2010 for the EU plus Iceland, 
Norway, and Switzerland5. Inpatient hospital costs for acute stroke accounts for 70% of first-year 
post-stroke costs6. Severe strokes (NIHSS>20) cost twice as much as mild strokes, despite 
similar diagnostic testing 6. Comorbidities such as ischemic heart disease and atrial fibrillation 
predict higher costs 6. The American Heart Association projects the total cost of stroke, which 
encompasses both direct and indirect spending, to increase from $105.2 billion in 2012 to $240.7 
billion by 20307. It is likely that estimates of morbidity and cost burden, based on traditional 
measures such as physical disability and healthcare costs, underestimate the burden of 
cerebrovascular disease. It is increasingly appreciated, for example, that subclinical 
cerebrovascular disease—including so-called silent infarction identified on brain imaging in 
<=28% of the population aged >65 years8  and ischemic white matter disease—is associated with 
memory loss, dementia, gait impairment, and other functional disability9. 
 Stroke is preventable to a large extent due to modifiable risk factors10. Targeting risk 
factors such as high blood pressure, smoking, obesity, diabetes mellitus, atrial fibrillation, 
dyslipidaemia and lack of physical activity may have already contributed to the observed 
improvement of stroke incidence, mortality and disability-adjusted life-years (DALYs) in high-
income countries over the last two decades. However the absolute numbers of incidence stroke, 
survivors and stroke related death as well as DALYS lost has increased, partly due to the rising 
numbers in low and middle-income countries2. 
 While ischemic strokes comprise the highest number of stroke, most of the global burden 
of stroke measured in proportion to mortality and by DALYs is allocated to haemorrhagic 
stroke11. Low and middle-income countries endure 80% of death due to haemorrhagic stroke11.  
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 The burden of stroke in people younger than 65 has increased over the last decades, the 
incidence has increased worldwide by 25% among adults age 20 to 64.  There is a concerning 
shift of the overall stroke burden towards younger age groups, particularly in low and middle-
income countries. The epidemic rise in cardiovascular risk factors in young adults in some 
regions such as Russia, China as well as India has contributed to the increase in stroke burden 
among the younger population12-17. Stroke is an especially serious problem in Asia, which has  
more than 60% of the world’s population, and many of its  countries are “developing” 
economies. Stroke mortality is higher in Asia than in Western Europe, the Americas or 
Australasia, similar to Eastern Europe 18. 
 Besides geographical disparities there are also clear disparities between different race and 
ethnic groups. For example there is an (200-300%) excess mortality for blacks age 45 to 65 
compared to the withe population in the US19-21. About 50% of this excess is explained by 
traditional risk factors mainly hypertension as well as differences in socio-economic status, 
highlighting the importance of stroke prevention interventions aimed at minority groups22.  
 Inequality in stroke mortality is also observed in women compared to men in many 
regions around the globe1. The WHO reported an excess of total stroke-related deaths among 
women compared with men between 1990 and 2006, of which 60% occurred in those aged over 
75 years23. A study performed in 8 different European countries found that the risk of stroke 
increased by 9% per year in men and 10% per year in women24. This excess risk may be partly 
explained by the longer life span of women compared with men and by the fact that hypertension 
and atrial fibrillation, key risk factors for stroke, are more frequent in women than in men 25. But 
further differences in vascular biology, immunity, coagulation, hormonal profiles, life style 
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factors and societal roles seem to contribute, especially due to risks related to pregnancy and the 
postpartum state 25.  
 In conclusion in high income countries a substantial decrease of stroke incidence, 
mortality and disability-adjusted life-years (DALYs) has been achieved in the last decades, most 
likely due to improvement in primary and secondary prevention as well as acute stroke 
treamtment and neurorehabilitation. However, stroke remains an important cause of disability 
and death worldwide. Globally, the burden of stroke has increased substantially over the past 
decades because of expanding population numbers and ageing as well as increased prevalence of 
many modifiable stroke risk factors especially in low and middle income countires. The number 
of patients who will need care by clinicians with expertise in neurological conditions will 
continue to grow in coming decades2. 
 
 
Stroke etiology and secondary prevention 
At least one stroke survivor out of six will suffer another stroke within 5 years26. To prevent 
stroke recurrence patients are treated based on the presumed underlying etiology. Patients with 
symptomatic high-grade carotid stenosis undergo carotid endarterectomy or stenting, patients 
with cardioembolic infarcts due to atrial fibrillation are treated with oral anticoagulants and 
patients with infective endocarditis are treated with antibiotics. But how do we identify the 
underlying cause?  
 Various stroke etiologic classification systems have been developed. The TOAST 2 
classification system is the most commonly used in patients with ischemic stroke. By means of 
clinical judgment applied to results of the patient’s neurological exam, brain imaging (CT/MRI), 
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standard 24-hour electrocardiography, echocardiography and ultrasound of extra and intracranial 
arteries, the most likely etiology is determined. Specifically, the TOAST system classifies 
ischemic strokes as due to large-vessel atherosclerosis, cardioembolic source, small vessel 
disease, other “determined” causes, and stroke of “undetermined” etiology27. The last mentioned 
category comprises also those patients without known cause due to incomplete evaluation or due 
to the occurrence of multiple competing causes.  
 Other somewhat newer sub-classification systems, the Causative Classification of Stroke 
(CCS) system28 and the A-S-C-O classification29 are also available. The CSS system is 
advancing the accuracy of ischemic stroke subtype diagnosis by taking into account the level of 
diagnostic evidence in order to devise the “most likely mechanism” in the presence of multiple 
potential causes. The process goes beyond the results of etiologic testing and basically 
standardizes the clinical decision-making process, replacing an algorithm for the individual 
clinician’s judgment, to arrive at the cause of the stroke. The A-S-C-O classification system does 
not determine a final stroke etiology per se but rather takes into account the combination of all 
potential mechanisms graded by their impact, thus this approach is more descriptive, or 
phenotypic. 
 Despite the fact that the newer classification systems may have better discriminatory 
value, in clinical practice we are unable to identify the underlying cause with reasonable 
certainty in up to 30% of patients 30. Thus in these patients secondary prevention cannot be 
tailored towards the underlying etiology and the relative benefits of antiplatelet and anticoagulant 
therapy remain uncertain31. 
To address part of this problem recently a group of scientists suggested defining a new entity 
within the “undetermined” category and they called it embolic stroke of undetermined source 
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(ESUS)30 if even after extensive evaluation no underlying cause can be identified. They proposed 
that most of these types of stroke are of an embolic nature. 
 Diverse low-risk sources are the presumed origin of thromboemboli causing infarcts in 
embolic strokes of undetermined source, including, low-burden or undetected paroxysmal atrial 
fibrillation, patent foramen ovale, mild left ventricular dysfunction, aortic-arch atherosclerosis, 
and nonstenosing atherosclerotic plaques in cervical and intracranial arteries31. Currently there 
are two trials ongoing (RESPECT ESUS and ATTICUS), one was terminated early for futility 
(NAVIGATE ESUS), which aim to prove that all these patients might benefit from the novel 
anticoagulants. 
 But then again how well do old and newer stroke classification schemes measure up to 
recent advances in precision medicine? Blood biomarkers, for example may provide additional 
insight into stroke etiology. Distinct gene expression profiles were able to accurately 
differentiate stroke patients with atrial fibrillation from patients with large artery stenosis32. 
Several studies have confirmed that natriuretic peptides, mainly N-terminal brain natriuretic 
peptide (NT-proBNP)33 and mid-regional atrial natriuretic peptide (MRproANP)34 are able to 
identify primarily cardioembolic stroke subtypes as well as stroke risk. In addition higher 
NTproBNP levels were associated with a relative benefit of warfarin compared with aspirin for 
prevention of recurrent stroke35. 
 If confirmed in randomized controlled trials blood biomarkers may help in detecting 
underlying etiology and thus guide secondary prevention36. 
Disability rehabilitation and socioeconomic burden 
Stroke is the leading cause of long-term disability in the US especially in the elderly population 
in which stroke incidence is highest. From the 795000 new sufferes of a stroke, 26% remain 
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disabled in basic activities of daily living (Framingham cohort) and 50% have reduced mobility 
due to hemiparesis 37. Aphasia and depression are other frequent causes for disability 37.  In the 
US, stroke is third in disability and socioeconomic impact (direct and indirect cost) after back 
pain and osteoarthritis. It causes total direct costs of 20-30 billion USD and indirect costs of 15-
25 billion USD 38. Costs depend on the level of disability and are generally higher for 
hemorrhagic as compared with ischemic stroke 39 as is the loss in disability adjusted life years 
(DALY) 40. 
The global burden of disease study 2013 found an increase in stroke incidence and DALYs in 
younger adults aged 20-64 years. This increase was most prevalent in developing contries and 
more due to hemorrhagic than ischemic stroke 41. Stoke burdens clearly is a function of 
socioeconomic status with greater odds of disability in patients with lower education and income 
42. 
Evidence that specialized stroke rehabilitation reduces long term disability and stroke-related 
costs exists for different contries and health care systems including Switzerland 43, UK 44, 45 and 
Japan 46. Cost effectiveness depends on the severity of disability: patients with moderate 
disability benefit more than those with severe or mild stroke severity 46. 
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